tobias.meili@wenger-plattner.ch
Write
Copy
Copied
+41 61 279 70 60
Call
Tobias Meili is a Partner in the practice groups Governance & Compliance, Life Sciences & Health Law, and Corporate & M&A. He advises clients, particularly in the life sciences sector, on commercial and corporate law, especially on corporate governance (including corporate responsibility issues), restructuring, mergers and acquisitions (M&A), and contract and technology law. His area of activity also includes internal investigations as an examiner or investigator appointed by FINMA or companies.
Due to his many years of experience in a leading position in the legal department of a formerly SMI-listed multinational corporation and an international consulting and technology company, Tobias Meili is familiar with the structures, processes, and challenges of large companies. In his legal practice, he combines an authentic, pragmatic, and solution-oriented advisory approach with solid legal expertise and negotiation skills.
« My goal is to achieve genuine 'business partnering' through close collaboration with the client, thereby creating real added value for them.
Partner
General Counsel Corporate Legal; Corporate Secretary
Head Legal CH; Senior Counsel MA
Senior Associate
Foreign Legal Counsel
LL.M.
Dr. iur.
Associate
Junior Associate
lic.iur.
Member; Chair of the Governance Committee
Lecturer in Law
Board Member
« I appreciate Tobias' pragmatic and competent support: he is a reliable member of our team.
Thomas Meier
CEO Bachem Group
« Knowledge. Kind
Client
IFLR 1000
« Tobias Meili and the Wenger Plattner team actively supported SWICA in a complex restructuring, from the innovative concept to the concrete implementation.
Benjamin Marti
General Counsel / COO SWICA Healthcare Insurance Ltd.
2024
May 6, 2024
Life Science 2024 | Switzerland: Trends & Developments
André S. Berne | Tobias Meili
April 19, 2024
Drug & Medical Device Litigation 2024 - Practical cross-border insights into drug and medical device litigation
André S. Berne | Carlo Conti | Tobias Meili
March 5, 2024
Digital Health Laws and Regulations Switzerland 2024
André S. Berne | Martina Braun | Carlo Conti | Tobias Meili
January 30, 2024
Life Sciences & Pharma IP Litigation 2024
André S. Berne | Tobias Meili | Damian Schai | Isabel Wahl-Zeller
April 17, 2023
Drug & Medical Device Litigation 2023 - Practical cross-border insights into drug and medical device litigation
November 4, 2021
Rechtlicher Rahmen der Unternehmensverantwortung in der Schweiz
Tobias Meili
March 30, 2021
Newsletter 2/21: Das revidierte Schweizer Datenschutzgesetz (DSG): Neuerungen und Auswirkungen auf Unternehmen
Martina Braun | Tobias Meili
February 9, 2021
Indirekter Gegenvorschlag zur Unternehmensverantwortungs-Initiative
December 1, 2020
Unternehmensverantwortung
November 19, 2020
Wirksame Unternehmensverantwortung: Wieso der indirekte Gegenvorschlag die bessere Lösung ist
July 31, 2017
„Wie ernst meinen es Schweizer Unternehmen mit verantwortungsvollem Wirtschaften?“ Streitgespräch zwischen Tobias Meili, Syngenta und Mark Herkenrath, Alliance Sud
December 31, 2000
Der Schutz von Know-how nach schweizerischem und internationalem Recht - Anpassungsbedarf aufgrund des TRIPS-Abkommens?